Skip to main content

Table 2 Faecal Microbiota Transplantation usage in human studies of obesity/metabolic syndrome

From: A review on gut microbiota: a central factor in the pathophysiology of obesity

Paper

No. patient

Demographic

Type of study

Mode of delivery

Country of Study

Frozen / fresh

Outcomes

Significant Adverse Events

Allegretti et al. [129]

22

11 = allogenic lean FMT

11 = placebo

Obese BMI > 35 without metabolic complications

DBRCT*

1:1

Capsules

USA

Unrelated donor

Frozen stool

No change in GLP1 in either group

No significant changes in obesity biomarkers

No changes in BMI

Sustained shift of microbiome towards donor profile

Nil

Vrieze et al. [47]

18

9 = Lean allogenic

9 =

autologous FMT

Treatment naïve males with metabolic syndrome

RCT* placebo controlled pilot study

1:1

Nasoduodenal tube

Netherlands

Unrelated donor

Fresh stool

Improvement in peripheral insulin sensitivity at 6 weeks in allogenic FMT

Gut bacterial diversity significantly increased post allogenic FMT

Nil

Smits et al. [130]

20

10 = allogenic lean vegan

FMT

10 = autologous FMT

Male cohort with metabolic syndrome

DBRCT pilot study

1:1

Nasoduodenal tube

Netherlands

Unrelated donor

Fresh stool

No changes in faecal diversity 2 weeks post FMT

Allogenic FMT shifted microbiome profile towards vegan

No changes in vascular inflammation

Nil

  1. DBRCT: double-blinded randomised control trial, RCT: randomised control trial